Monopar Therapeutics Inc - MNPR Enterprise Value-to-Sales Ratio

Official company branding of monopartx.com (MNPR)

The development of targeted agents that destroy tumors from within shapes the financial profile of Monopar Therapeutics (MNPR). The current EV/Sales value on this chart shows that the metric stands at 0.00. Capital optimization is based on the market launch of radiopharmaceuticals and the success of oral cancer therapy, where a steady patient inflow and high efficacy await final FDA approval.

Monopar Corp (MNPR): Company Value to Revenue from 11/23/2025 to 11/20/2026

Monopar Pharma - analytical breakdowns and key metrics (MNPR)

Fundamental company valuation:MNPR, monopartx.com
Manufactured products of Monopar Therapeutics Inc

Investing in Monopar Therapeutics (MNPR) requires strict fundamental control due to the high volatility of the biotech sector. This indicator compares the total enterprise value, adjusted for net debt, against the volume of generated revenue. Analyzing the firm's valuation via the EV/Sales multiple allows for a real-time assessment of whether the asset is overbought. This is critical for Monopar Therapeutics (MNPR), as the risks of clinical failures and pressure from biosimilars could sharply impair capital. The trend of this metric helps avoid entering a position at local peaks.

Competitor analysis